| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:11268341 | IVR | 0.0005 mg | 0.0005 mg | Changes in white blood cell (WBC) populations | Immunological endocrine-mediated perturbations |
| IVR | 0.0005 mg | 0.0005 mg | Alterations in immune responses | Immunological endocrine-mediated perturbations | |
| IVR | 0.0005 mg | 0.0005 mg | Changes in B-cell populations | Immunological endocrine-mediated perturbations | |
| PMID:8182612 | IVR | 2 mg/kg | 2 mg/kg | Decreased uterine weights | Reproductive endocrine-mediated perturbations |
| IVR | 2 mg/kg | 2 mg/kg | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:8821744 | IVR | 0.1 mg/kg | 0.1 mg/kg | Increased levels of adrenocortical hormones (ACTH) | Metabolic endocrine-mediated perturbations |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Affects neuronal signaling | Neurological endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.